4 documents found, page 1 of 1
Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist th...
Pitt, Bertram; Anker, Stefan D.; Lund, Lars H.; Coats, Andrew J. S.; Filippatos, Gerasimos; Rossignol, Patrick; Weir, Matthew R.; Friede, TimBackground: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). Objectives: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAA...
Sex-stratified patterns of emergency cardiovascular admissions prior and during...
Gajewski, Piotr; Błaziak, Mikołaj; Urban, Szymon; Garus, Mateusz; Braunschweig, Frieder; Caldeira, Daniel; Gawor, Antoni; Greenwood, John P.The COVID-19 pandemic has had a significant impact on global public health, with long-term consequences that are still largely unknown. This study aimed to assess the data regarding acute cardiovascular hospital admissions in five European centers before and during the pandemic. A multicenter, multinational observational registry was created, comparing admissions to the emergency departments during a 3-months p...
Patient profiling in heart failure for tailoring medical therapy: a consensus d...
Rosano, Giuseppe M. C.; Moura, Brenda; Metra, Marco; Böhm, Michael; Bauersachs, Johann; Ben Gal, Tuvia; Adamopoulos, Stamatis; Abdelhamid, MagdyDespite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays...
Patiromer for the management of hyperkalaemia in patients receiving renin–angio...
Butler, Javed; Anker, Stefan D.; Siddiqi, Tariq Jamal; Coats, Andrew J. S.; Dorigotti, Fabio; Filippatos, Gerasimos; Friede, Tim; Göhring, Udo‐MichaelAims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screeni...